Terms: = Breast cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Prognosis
64 results:
1. Potential Value of hsp90α in prognosis of Triple-Negative breast cancer.
Wang HF; Chen Y; Cao B; Pei J
Med Sci Monit; 2024 Mar; 30():e943049. PubMed ID: 38553816
[TBL] [Abstract] [Full Text] [Related]
2. Immunogenic cell death-related classification reveals prognosis and effectiveness of immunotherapy in breast cancer.
Zhu L; Wu Y; Zhao H; Guo Z; Bo B; Zheng L
Sci Rep; 2024 Jan; 14(1):2025. PubMed ID: 38263419
[TBL] [Abstract] [Full Text] [Related]
3. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma.
Dong Y; Yu X; Song H; Chen Q; Zheng B; Ji X; Xu M; Liu J; Sun X; Wang Q; Ren R; Lu H
Cell Cycle; 2023; 22(23-24):2566-2583. PubMed ID: 38164943
[TBL] [Abstract] [Full Text] [Related]
4. BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate.
Huang X; Shi D; Zou X; Wu X; Huang S; Kong L; Yang M; Xiao Y; Chen B; Chen X; Ouyang Y; Song L; Jian Y; Lin C
Theranostics; 2023; 13(1):339-354. PubMed ID: 36593950
[No Abstract] [Full Text] [Related]
5. Construction and validation of an aging-related gene signature for prognosis prediction of patients with breast cancer.
Li J; Qi C; Li Q; Liu F
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1741. PubMed ID: 36323529
[TBL] [Abstract] [Full Text] [Related]
6. Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients.
Yu H; Lv W; Tan Y; He X; Wu Y; Wu M; Zhang Q
J Transl Med; 2022 Jul; 20(1):328. PubMed ID: 35864548
[TBL] [Abstract] [Full Text] [Related]
7. Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals.
Li R; Hu X; Shang F; Wu W; Zhang H; Wang Y; Pan J; Shi S; Dong C
Acta Biomater; 2022 Aug; 148():218-229. PubMed ID: 35705171
[TBL] [Abstract] [Full Text] [Related]
8. PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells.
Calvillo-Rodríguez KM; Mendoza-Reveles R; Gómez-Morales L; Uscanga-Palomeque AC; Karoyan P; Martínez-Torres AC; Rodríguez-Padilla C
Oncoimmunology; 2022; 11(1):2054305. PubMed ID: 35402082
[TBL] [Abstract] [Full Text] [Related]
9. Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative breast cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation.
Pai JT; Chen XH; Leu YL; Weng MS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163593
[TBL] [Abstract] [Full Text] [Related]
10. Identification of AHSA1 as a Potential Therapeutic Target for breast cancer: Bioinformatics Analysis and in vitro Studies.
Shi W; Qi L; You XB; Chen YC; Xu YL; Yu WB; Huang MY; Zhao H; Lu JJ
Curr Cancer Drug Targets; 2022; 22(2):142-152. PubMed ID: 35034596
[TBL] [Abstract] [Full Text] [Related]
11. Theaflavin-3-gallate, a natural antagonist for hsp90: In-silico and in-vitro approach.
Bhadresha K; Kumar SP; Brahmbhatt J; Patel C; Pandya P; Jain N; Rawal R
Chem Biol Interact; 2022 Feb; 353():109774. PubMed ID: 34958756
[TBL] [Abstract] [Full Text] [Related]
12. hsp90 regulates the tumorigenic function of tyrosine protein kinase in osteosarcoma.
Yao ZP; Zhu H; Shen F; Gong D
Clin Exp Pharmacol Physiol; 2022 Mar; 49(3):380-390. PubMed ID: 34767669
[TBL] [Abstract] [Full Text] [Related]
13. Long non-coding RNA NKILA regulates expression of hsp90α, NF-κB and β-catenin proteins in the MCF-7 breast cancer cell line.
Tibatan MA; Önay Uçar E
Mol Biol Rep; 2021 May; 48(5):4563-4571. PubMed ID: 34125329
[TBL] [Abstract] [Full Text] [Related]
14. A novel hsp90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer.
Park JM; Kim YJ; Park S; Park M; Farrand L; Nguyen CT; Ann J; Nam G; Park HJ; Lee J; Kim JY; Seo JH
Mol Cancer; 2020 Nov; 19(1):161. PubMed ID: 33218356
[TBL] [Abstract] [Full Text] [Related]
15. Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in breast cancer.
Lin T; Qiu Y; Peng W; Peng L
Biomed Res Int; 2020; 2020():2148253. PubMed ID: 33145341
[TBL] [Abstract] [Full Text] [Related]
16. KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
Chen J; Liu C; Cen J; Liang T; Xue J; Zeng H; Zhang Z; Xu G; Yu C; Lu Z; Wang Z; Jiang J; Zhan X; Zeng J
Medicine (Baltimore); 2020 May; 99(18):e19986. PubMed ID: 32358373
[TBL] [Abstract] [Full Text] [Related]
17. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
[TBL] [Abstract] [Full Text] [Related]
18. USP22-dependent hsp90aB1 expression promotes resistance to hsp90 inhibition in mammary and colorectal cancer.
Kosinsky RL; Helms M; Zerche M; Wohn L; Dyas A; Prokakis E; Kazerouni ZB; Bedi U; Wegwitz F; Johnsen SA
Cell Death Dis; 2019 Dec; 10(12):911. PubMed ID: 31801945
[TBL] [Abstract] [Full Text] [Related]
19. FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer.
Mangé A; Coyaud E; Desmetz C; Laurent E; Béganton B; Coopman P; Raught B; Solassol J
Theranostics; 2019; 9(23):7003-7015. PubMed ID: 31660083
[No Abstract] [Full Text] [Related]
20. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
[Next]
